Premium
Plasma microRNA vary in association with the progression of Alzheimer’s disease
Author(s) -
Guévremont Diane,
Tsui Helen,
Knight Robert,
Fowler Christopher J,
Masters Colin L,
Martins Ralph N,
Abraham Wickliffe C,
Tate Warren P,
Cutfield Nick,
Williams Joanna M
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.047469
Subject(s) - microrna , disease , neurodegeneration , taqman , alzheimer's disease , oncology , bioinformatics , biology , biomarker , medicine , real time polymerase chain reaction , gene , genetics
Abstract Background Early intervention in Alzheimer’s disease (AD) requires development of an easily administered test able to identify those at risk. Focusing on microRNA robustly detected in plasma and standardizing the analysis, we sought to identify disease‐stage specific biomarkers. Method Using TaqMan microfluidics arrays and a statistical consensus approach, we assessed plasma levels of 182 neurodegeneration‐related microRNA, in cohorts of amyloid‐positive, mild cognitive impairment and AD participants, relative to their respective controls. Result Plasma microRNA were shown to be dynamically altered with AD progression. Distinct disease stage microRNA biomarkers were identified, and these were shown to predict membership of the groups (AUC >0.8). Bioinformatics demonstrated that these microRNA target known AD‐related pathways. Furthermore, a significant correlation was found between three microRNA and amyloid‐ß load. Conclusion Our results show that microRNA signatures alter during the progression of AD, relate to the underlying disease pathology and may prove to be useful diagnostic markers.